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Background.  OP0595 is a diazabicyclooctane which (i) acts as PBP2-active antibacterial, 29 
(ii) inhibits Class A and C -lactamases, and (iii), like mecillinam, gives -lactamase-30 
independent potentiation of -lactams targeting other PBPs.  We tested its behaviour 31 
against -lactam-resistant Enterobacteriaceae and non-fermenters. Methods.  Organisms 32 
were UK clinical isolates; MICs were determined by CLSI agar dilution for OP0595 alone or 33 
combined at 1-4 mg/L with aztreonam, biapenem, cefepime or piperacillin.  Results. MICs 34 
of OP0595 for Escherichia coli, Enterobacter, Citrobacter and Klebsiella spp. were mostly 35 
1-4 mg/L but values >4 mg/L were seen for minorities of isolates irrespective of other 36 
resistances, and for 50-60% of those with ertapenem resistance involving porin loss plus 37 
ESBL or AmpC activity.  OP0595 MICs for Serratia, Proteeae and non-fermenters mostly 38 
were >4 mg/L. When its MIC was <4 mg/L, OP0595’s antibacterial activity dominated 39 
combination activity.  For OP0595-‘resistant’ (MIC >4 mg/L) isolates with Class A or C -40 
lactamases OP0595 achieved strong potentiation of substrate lactams, contingent on -41 
lactamase inhibition. Lactamase-independent potentiation was evident with aztreonam, 42 
cefepime and piperacillin – less so for biapenem – for many OP0595-resistant 43 
Enterobacteriaceae with Class B carbapenemases, which are not inhibited by OP0595.  44 
OP0595 acted solely as a -lactamase inhibitor for non-fermenters. Conclusions. OP0595 45 
inhibited Enterobacteriaceae, not non-fermenters; its combinations had broad activity 46 
versus Enterobacteriaceae, largely contingent on OP0595’s antibacterial activity but also 47 
on inhibition of class A and C -lactamases and on the -lactam-enhancer effect, which 48 
allowed activity against many OP0595-resistant metallo--lactamase-producing 49 
Enterobacteriaceae. For non-fermenters OP0595 acted only as a -lactamase inhibitor. 50 
51 
Introduction 52 
The proliferation of extended-spectrum and carbapenem-hydrolysing lactamases 53 
challenges the continued dominance of lactam-based therapies, which are ‘Standard-of-54 
Care’ for most severe infections in non-allergic patients. 55 
 Developing a single lactam that evades all the now-prevalent lactamases is 56 
challenging, and a more realistic prospect is to combine a lactam that evades some 57 
lactamases with an inhibitor that inactivates others, thereby achieving overall breadth of 58 
spectrum.  Aztreonam/avibactam exemplifies this approach, with aztreonam being stable to 59 
MBL- and OXA-48 carbapenemases and with avibactam protecting against aztreonam-60 
hydrolysing extended-spectrum, AmpC and KPC lactamases.1,2  This strategy might be 61 
extended by employing a lactamase inhibitor with secondary activities.  Avibactam has 62 
only marginal antibacterial activity, with MICs around 16 mg/L for Escherichia coli and 63 
higher for other Gram-negatives, but other diazabicyclooctanes have greater activity.  64 
OP0595, which was discovered independently by Meiji and Fedora,3 in particular, binds 65 
strongly to PBP2 of Enterobacteriaceae, thereby achieving antibacterial activity as well as 66 
acting as an inhibitor of class A and C lactamases. In addition, and like mecillinam,4-6 67 
which also binds to PBP2,7 OP0595 seems able to potentiate PBP-3-active lactams via a 68 
lactamase-independent ‘enhancer’ effect, hypothesised to reflect concurrent attack on 69 
different PBPs by the two molecules.3 70 
 In the present study we characterised the activity of OP0595 combined with 71 
aztreonam, biapenem, cefepime and piperacillin against Enterobacteriaceae and non-72 
fermenters with potent and clinically-frequent -lactamases.   73 
  74 
Materials and methods 75 
Antibiotics 76 
OP0595, avibactam, biapenem and cefepime powders were provided by Meiji (Yokohama, 77 
Japan); aztreonam, ceftazidime and piperacillin were purchased from Sigma (Poole, UK). 78 
 79 
Bacteria 80 
Bacteria were recent reference submissions to Public Health England’s Antimicrobial 81 
Resistance and Healthcare Associated Infections Reference Unit from UK diagnostic 82 
laboratories. Numbers of isolates by species and resistance mechanism are detailed in 83 
Tables 1 and 2. Carbapenemase genes were sought by PCR and sequencing; outer 84 
membrane protein expression was previously characterised by gene sequencing and 85 
protein profiles, as described previously.8 Isolates included as carbapenemase producers 86 
may have had additional extended-spectrum -lactamases (ESBLs) or AmpC enzymes; 87 
isolates included as ESBL and AmpC producers lacked carbapenemases but may have 88 
had additional penicillinases; those included as controls lacked ESBLs, AmpC enzymes or 89 
carbapenemases but may have produced penicillinases   90 
 91 
Susceptibility testing 92 
Susceptibility testing was performed by CLSI agar dilution,9 using aztreonam, biapenem, 93 
cefepime and piperacillin combined with OP0595 at 1, 2 and 4 mg/L for Enterobacteriaceae 94 
and with OP0595 at 4 mg/L, only, for non-fermenters.  Ceftazidime was tested alone and in 95 
combination with avibactam at 4 mg/L. 96 
 97 
Results 98 
Antibacterial activity of OP0595  99 
MIC distributions of OP0595, by species and irrespective of resistance mechanisms, are 100 
shown in Table 1.   MICs for Escherichia coli, Klebsiella spp. and Enterobacter spp. were 101 
mostly 1-4 mg/L, though values exceeding 4 mg/L were recorded for 9/50 Enterobacter 102 
spp. and 26/118 Klebsiella spp.  MICs of OP0595 for all the Morganella morganii and 103 
12/15 Serratia spp. isolates exceeded 4 mg/L, as did those for 29/30 Acinetobacter and the  104 
P. aeruginosa isolates tested   MICs were largely unrelated to known resistance 105 
mechanisms, except that values were >4 mg/L for 15/28 ertapenem-resistant, porin-106 
deficient E. coli, Klebsiella and Enterobacter spp. with ESBL or AmpC enzymes versus 107 
6/100 ertapenem-susceptible isolates of E. coli, Klebsiella and Enterobacter spp. or 108 
Citrobacter spp.) with the same lactamases (p <0.001, chi-squared test).   These data 109 
suggest that porin loss can restrict entry of OP0595. 110 
 111 
OP0595 in combination with lactams versus Enterobacteriaceae 112 
Susceptibility data for OP0595 in combination with aztreonam, biapenem, cefepime and 113 
piperacillin are summarised in Table 2. For convenient review, results are graded against 114 
the more stringent of CLSI9 or EUCAST (http://www.eucast.org) criteria for the partner -115 
lactam.  These values were considered to represent the lowest breakpoints that any 116 
regulatory agency might reasonably adopt. They should not be construed as definitive 117 
breakpoints, particularly for ceftazidime/avibactam, which has recently been given a 118 
breakpoint of 8+4 mg/L by the FDA, based upon a 2+0.5 g every 8h regimen, and where 119 
CLSI and EUCAST reviews are pending.   120 
On this rationale, we graded susceptible <1 mg/L and resistant >4 mg/L for 121 
aztreonam, ceftazidime and cefepime against Enterobacteriaceae, matching EUCAST 122 
values for these -lactams alone. For piperacillin we graded susceptible as MIC <8 mg/L 123 
and resistant as MIC >16 mg/L again adopting EUCAST values. In all these cases CLSI 124 
breakpoints are equal or higher.  For biapenem, which has no CLSI or EUCAST 125 
breakpoints, we graded susceptible <1 mg/L and resistant >4 mg/L, matching CLSI criteria 126 
for imipenem and meropenem and both CLSI and EUCAST criteria for doripenem; 127 
EUCAST breakpoints for imipenem and meropenem are higher. 128 
  Combination performance against Enterobacteriaceae was largely dominated by the 129 
antibacterial activity of OP0595 itself, since the concentrations used (1-4 mg/L) were 130 
equalled or exceeded the molecule’s MIC for most of the test strains (Table 2).  With 131 
OP0595 at 4 mg/L, >80% ‘susceptibility’ was achieved by all combinations versus all 132 
resistance groups, including MBL producers. Susceptibility rates >90% were achieved for 133 
all combinations except (i) biapenem/OP0595 against AmpC-derepressed strains, where 134 
performance was constrained by the inclusion of M. morganii, a species that was inherently 135 
less susceptible than other Enterobacteriaceae to both biapenem and OP0595; (ii) 136 
piperacillin/OP0595 against isolates that combined ESBL or AmpC activity with porin loss, 137 
and (iii) cefepime/OP0595 against MBL producers – where the more striking point is that 138 
35/40 isolates were susceptible and that the aztreonam/, biapenem/ and piperacillin/ 139 
OP0595 combinations did achieve 90% activity, even though only 31/40 isolates (77.5%) 140 
were inhibited by OP0595 itself at 4 mg/L.   141 
 Ceftazidime/avibactam 4 mg/L, tested as a comparator, had MICs <1 mg/L 142 
(‘susceptible’ on the criteria used) for >90% of isolates in the ertapenem-susceptible ESBL 143 
and AmpC groups, and for those with KPC and OXA-48 carbapenemases.   However 144 
ceftazidime/avibactam MICs were <1 mg/L for only 19/28 (67.8%) of the ertapenem-145 
resistant isolates that combined AmpC or ESBL activity with impermeability, with 146 
intermediate activity (MIC 2-4 mg/L) for eight of the remaining nine. MICs of 147 
ceftazidime/avibactam exceeded 4+4 mg/L for isolates with MBLs in 39/40 cases. 148 
 149 
OP0595 combinations versus Enterobacteriaceae resistant to OP0595 4 mg/L 150 
MIC data for Enterobacteriaceae isolates with OP0595 MICs >4 mg/L were further 151 
explored, to gain insight into the molecule’s secondary activities.  MIC data for OP0595-152 
resistant isolates with ESBLs and AmpC enzymes are summarised in Table 3, and those 153 
for OP0595-resistant isolates with carbapenemases are line-listed in Table 4. 154 
Strong potentiation was seen for ESBL substrates - i.e. aztreonam, cefepime and 155 
piperacillin - against OP0595-resistant ESBL producers. Similarly, strong potentiation was 156 
seen for AmpC substrates (aztreonam, piperacillin) against AmpC-hyperproducing 157 
OP0595-resistant E. coli, Enterobacter and Klebsiella spp.  Weaker potentiation was seen 158 
for cefepime against AmpC producers, doubtless because cefepime is a weaker substrate 159 
for AmpC enzymes; nevertheless, and notably, the geometric mean MIC of cefepime for 160 
ertapenem-resistant porin-deficient AmpC hyperproducers was reduced from 6.4 mg/L to 161 
0.89 with OP0595 at 1 mg/L and to 0.076 mg/L with OP0595 at 4 mg/L.   More generally, 162 
higher concentrations of OP0595 were needed to potentiate partner agents against 163 
ertapenem-resistant than against ertapenem susceptible-strains with ESBL and AmpC -164 
lactamases, again implying that porin loss restricts uptake of the diazobicyclooctane 165 
Potentiation by OP0595 was seen for piperacillin against AmpC-hyper-producing M. 166 
morganii and Serratia spp., which were inherently less susceptible to the antibacterial 167 
activity of OP0595, with most MICs >4 mg/L.  Derepressed AmpC gave less protection 168 
against aztreonam in these species than in E. coli, Klebsiella or Enterobacter spp. but, 18- 169 
to 55-fold reductions in geometric mean MIC were achieved when the diazabicyclooctane 170 
was incorporated in the agar at 4 mg/L, with 3.3- to 17- fold MIC reductions for cefepime.    171 
Potentiation against ESBL and AmpC groups was weaker for biapenem, which, like 172 
other carbapenems, is a poor substrate for these enzymes.10 Even so, OP0595 at 4 mg/L 173 
achieved >5-fold reductions in geometric mean biapenem MICs both for ertapenem-174 
resistant ESBL producers and – irrespective of ertapenem resistance – for AmpC-175 
hyperproducing E. coli, Enterobacter and Klebsiella spp., though with little potentiation 176 
against AmpC-derepressed M. morganii.  Avibactam similarly potentiated ceftazidime 177 
against ESBL and AmpC producers with the distinction, compared with aztreonam/OP0595 178 
and cefepime/OP0595,that derepressed M. morganii AmpC gave greater (avibactam-179 
reversed) resistance to ceftazidime than to either aztreonam or cefepime.  For almost all 180 
groups with ESBLs or AmpC enzymes, the geometric MICs of aztreonam-, cefepime- and 181 
piperacillin/OP0595 4 mg/L were lower than those of ceftazidime/avibactam 4 mg/L for the 182 
same isolates.  For ertapenem-resistant, porin-deficient organisms with ESBL and AmpC, 183 
the geometric mean MICs of aztreonam-, cefepime/OP0595 and piperacillin/OP0595 were 184 
<1 mg/L, thus falling into the ‘susceptible’ range, whereas values for ceftazidime/avibactam 185 
were 1.2 - 2.5 mg/L, falling into EUCAST’s intermediate MIC category for ceftazidime. 186 
OP0595  gave strong potentiation of all four partner agents against the six OP0595-187 
resistant isolates with KPC carbapenemases. In all cases the partner MICs were reduced 188 
below their target values when the inhibitor was present at 4 mg/L and, except for E. 189 
cloacae H401 and aztreonam this objective was achieved with 2 mg/L OP0595.   The fact 190 
that potentiation was seen with  biapenem, which is unlikely to be affected by any co-191 
produced -lactamase, supports the view that it was mediated by inhibition of the KPC 192 
enzyme, which OP0595 have been shown to inactivate in direct assays.3   193 
Aztreonam/OP0595, cefepime/OP0595 and ceftazidime/avibactam had good 194 
activity against the OP0595-resistant strains with OXA-48 -lactamase, with MICs below 1 195 
mg/L when 2-4 mg/L of inhibitor was present.  Three of the four OP0595-resistant strains 196 
with OXA-48 carbapenemase were highly resistant to the cephalosporins and aztreonam 197 
and, given that these oxyimino aminothiazolyl molecules are weak substrates for OXA-48 198 
enzyme or are stable1,11 potentiation is inferred largely to reflect inhibition of co-produced 199 
ESBLs or AmpC enzymes. The fourth OXA-48 strain (K. pneumoniae H483) was 200 
susceptible or intermediate to aztreonam, cefepime and ceftazidime, with MICs of 0.25-2 201 
mg/L, implying the absence of ESBLs or AmpC enzymes.  For this organism, OP0595 at 2 202 
or 4 mg/L still reduced aztreonam and cefepime MICs by eight-fold or more, suggesting an 203 
enhancer effect, whereas avibactam 4 mg/L reduced the ceftazidime MIC by only two-fold.  204 
Also notable were the comparative behaviours of biapenem (unlikely to be affected by any 205 
-lactamase besides OXA-48) and piperacillin (a substrate for OXA-48 as well as co-206 
produced ESBLs and penicillinases). Potentiation of biapenem by OP0595 was weak, with 207 
only two- to four-fold MIC reductions with the inhibitor at 2-4 mg/L.   For piperacillin, by 208 
contrast, MICs consistently exceeded 256 mg/L in the absence of OP0595 (including for 209 
the aztreonam-susceptible strain H483) and were reduced to <8 mg/L with OP0595 at 2-4 210 
mg/L.  It is difficult to reconcile the poor protection of biapenem and the good potentiation of 211 
piperacillin with a solely -lactamase-mediated mechanism (see Discussion). 212 
Turning, lastly, to the MBL producers: these comprise five aztreonam- susceptible 213 
or intermediate (MIC 0.25-2 mg/L) Enterobacteriaceae that were deduced to lack 214 
secondary ESBL or AmpC activity and four aztreonam-resistant organisms (MIC >64 mg/L) 215 
that putatively had ESBL or AmpC activity.  Strong potentiation of aztreonam by OP0595 216 
was seen for the aztreonam-resistant organisms, probably reflecting inhibition of these 217 
ESBLs or AmpC enzymes; more interestingly,  however, and even at 2 mg/L, OP0595 218 
reduced aztreonam MICs by eight-fold or more for 3/5 aztreonam-susceptible organisms; at 219 
4 mg/L it achieved this effect, which cannot readily be explained by -lactamase inhibition, 220 
for all five organisms.   221 
More generally, OP0595 at 2 mg/L achieved >8-fold potentiation of piperacillin, 222 
cefepime and biapenem for 8/9, 6/9, and 3/9 OP0595-resistant MBL producers, 223 
respectively. Corresponding proportions with OP0595 at 4 mg/L were 9/9, 9/9 and 4/9, 224 
respectively.  Given that the MBLs must have been the major contributors to biapenem 225 
resistance and to cefepime resistance in the low-aztreonam-MIC strains, it is again difficult 226 
to explain these results in terms of a -lactamase-inhibition alone, supporting the 227 
contribution of an enhancer effect (see Discussion).   Potentiation of ceftazidime by 228 
avibactam was seen for just one of the nine OP0595-resistant MBL producers; for the 229 
remainder, ceftazidime/avibactam MICs remained above 256 mg/L. 230 
 231 
P. aeruginosa and A. baumannii 232 
Results for non-fermenters are shown in Table 5.  Except for one P. aeruginosa all were 233 
resistant to OP0595 at 4 mg/L (Table 1). 234 
OP0595 potentiated aztreonam, cefepime and piperacillin against P. aeruginosa 235 
with derepressed AmpC or acquired PER or VEB -lactamases, but not against those with 236 
MBLs, nor against the -lactam-susceptible control strains.  Similar behaviour was seen 237 
between ceftazidime and avibactam, with avibactam 4 mg/L tending to achieve slightly 238 
greater fold potentiation of ceftazidime for AmpC-derepressed organisms than OP0595 4 239 
mg/L achieved for aztreonam and cefepime; neverthless the geometric mean MICs of 240 
aztreonam/OP0595, cefepime/OP0595 and ceftazidime/avibactam all remained similar to 241 
one another  242 
 OP0595 4 mg/L achieved c. 2.4 fold-potentiation of biapenem for the control P. 243 
aeruginosa strains, 4.3-fold potentiation for imipenem-susceptible (putatively OprD-244 
expressing) AmpC-derepressed organisms and 5.4-fold potentiation for 245 
imipenem/biapenem-resistant (OprD-deficient) AmpC derepressed isolates.  Previous 246 
experience shows that biapenem, like imipenem, is weakly affected even by inducible P. 247 
aeruginosa AmpC, and that this protection confers significant resistance if the organism 248 
also becomes impermeable via loss of OprD.12  The present results are compatible with 249 
these earlier findings, and with the fact that OP0595 inhibits the activity of purified 250 
pseudomonal AmpC enzyme.3  Similar potentiation is seen between imipenem and another 251 
diazabicyclooctane, MK-7655;13 also between imipenem and AmpC-inhibitory penems, 252 
such as BRL4271514 and bridged monobactams, e.g. Ro-48-1256.15 253 
In the case of A. baumannii, OP0595 achieved no significant potentiation of 254 
aztreonam, biapenem or cefepime against the control strains nor those with OXA or metallo 255 
carbapenemases. Similarly, avibactam did not potentiate ceftazidime against these groups. 256 
OP0595 did give weak potentiation of aztreonam, cefepime and piperacillin for isolates with 257 
AmpC-associated cephalosporin resistance, though geometric mean MICs remained high, 258 
with the lowest value (7.9 mg/L) recorded for cefepime/OP0595; similar behaviour was 259 
seen between ceftazidime and avibactam.  OP0595 potentiated piperacillin against the 260 
control A. baumannii strains, probably reflecting inhibition of co-produced penicillinases. 261 
 262 
Discussion 263 
These findings, for sizeable panels of multi-resistant organisms, extend the data reported 264 
Morinaka et al.3 for OP0595 combinations.  They support Morinaka’s conclusions that 265 
OP0595 has a triple activity, acting as an antibiotic, inhibitor of Class A and C -266 
lactamases, and as a -lactamase-inhibition-independent enhancer of partner -lactams 267 
that bind to PBP3. 268 
 The antibacterial activity of OP0595, which is associated with inhibition of PBP2,3is 269 
the simplest of these activities to define and was strongest against E. coli, Klebsiella and 270 
Enterobacter spp. As with mecillinam,16 which also exclusively attacks PBP2,3 activity was 271 
weaker against Morganella and Serratia spp. than against other Enterobacteriaceae. P. 272 
aeruginosa and A. baumannii were more resistant. This behaviour seems likely largely to 273 
reflect target insensitivity, or dispensability17 since OP0595 continued to act as an inhibitor 274 
of AmpC enzymes in all these species proving that it must be able to permeate them and 275 
evade efflux. 276 
This antibacterial activity of OP0595 dominated combination behaviour against 277 
Enterobacteriaceae (Table 2). However, OP0595’s -lactamase-inhibitory activity became 278 
apparent in the potentiation seen between OP0595 and substrate -lactams against those 279 
AmpC-, ESBL- and KPC- -lactamase-producing strains that were resistant to the 280 
antibacterial activity of OP0595 itself.  Major reductions in the MIC of the partner -lactam 281 
were evident even with OP0595 at 1 mg/L, equating to <0.125 x MIC OP0595 for these 282 
organisms.   Although it is impossible to completely disentangle the contributions of -283 
lactamase inhibition and the enhancer effect in this potentiation, a major contribution by -284 
lactamase inhibition is supported by: (i) potentiation being stronger with substrate -lactams 285 
than non-substrates, (ii) potentiation being stronger against organisms with Class A and C 286 
enzymes, which OP0595 inhibits,3 than against those with Class B enzymes, which are not 287 
inhibited and (iii) by potentiation extending to aztreonam-, cefepime- and piperacillin- 288 
combinations against AmpC-derepressed P. aeruginosa, whereas there was no 289 
potentiation of these -lactams by OP0595 against wild-type P. aeruginosa without 290 
derepression of AmpC. 291 
Evidence for the enhancer effect, which was unique to Enterobacteriaceae, came 292 
from OP0595’s frequent potentiation of -lactams that were not substrates for the 293 
organism’s -lactamase, particularly for the common, though not universal, potentiation of 294 
aztreonam and cefepime against aztreonam-susceptible (i.e. ESBL- and AmpC-negative) 295 
OP0595-resistant MBL-producing Enterobacteriaceae (Table 4). Potentiation was less 296 
consistent or extensive for biapenem and these findings are in keeping with the view that 297 
the enhancer effect arises when the PBP2-directed activity of OP0595 is combined with 298 
PBP3-targeted agents3 rather than those, like biapenem, that strongly bind PBP2.18 This 299 
view also accommodates the stronger potentiation of piperacillin than biapenem for strains 300 
with OXA-48 carbapenemase, even though both -lactams are substrates for this 301 
enzyme.12,19     302 
Given that the enhancer activity was demonstrable in OP0595-resistant strains, and 303 
was retained in an OP0595-resistant mutant,3 it clearly does not require the antibacterial 304 
activity of OP0595.   A plausible explanation lies in the observation that resistance to 305 
mecillinam commonly reflects compensatory mutations up-regulating FtsQAZ20-22 or 306 
increasing cellular levels of the regulatory molecule ppGpp,23 not to changes to PBP2 itself.  307 
It may be that these mutations prevent inhibition of PBP2 leading to cell death but that, with 308 
PBP2 still present and inhibited, the enhancer activity remains.  This hypothesis is 309 
compatible with the observation that an OP0595-selected E. coli mutant, lacked sequence 310 
changes to the PBP2 gene, pbp2.3 311 
Compared with ceftazidime/avibactam the major difference was that the various 312 
OP0595 combinations remained active, even at the very stringent definitions adopted, 313 
owing either to the antimicrobial activity of OP0595 or to its enhancer effect, against the 314 
great majority of MBL-producing Enterobacteriaceae (40/40 for aztreonam-OP0595, 36/40 315 
for cefepime-OP0595, 35/40 for biapenem-OP0595 and 39/40 for piperacillin-OP0595, all 316 
based on tests in the presence of 4 mg/L OP0595), whereas organisms were consistently 317 
resistant to ceftazidime/avibactam, as also found by others.24  Deeper comparison is 318 
difficult because (i) OP0595 and avibactam were tested in combination with different -319 
lactams, (ii) the final partner agent(s) for OP0595 remain to be decided, and (iii) final CLSI 320 
and EUCAST breakpoints may differ from the ‘most stringent’ values adopted here.  321 
Despite these caveats it is notable that OP0595 combinations more often retained full 322 
activity against ertapenem-resistant Enterobacteriaceae with ESBLs or derepressed AmpC 323 
than did ceftazidime/avibactam. For AmpC-derepressed P. aeruginosa, the performance of 324 
ceftazidime/avibactam, cefepime/OP0595 and aztreonam/avibactam was similar. 325 
In summary, and combined with Morinaka’s data,3 these results support the 326 
complex tripartite activity of OP0595, and indicate the potential for diazabicyclooctane 327 
combinations with a broader activity than ceftazidime/avibactam.   Major challenges 328 
remain, most obviously in the choice of partner agent for OP0595 and in assessing 329 
vulnerabilities to mutational resistance, both (i) for OP0595’s own activities and (ii) for 330 
combinations where, as with ceftazidime/avibactam, vulnerability can involve the -331 
lactamase increasing its substrate specificity rather than developing inhibitor resistance per 332 
se.25  333 
Acknowledgement.  The results for Enterobacteriaceae were presented at the 54th ICAAC, 334 
Washington DC, September 2014: Livermore DM et al. Poster F-942, 335 
Funding 336 
This work was funded by Meiji Seika Pharma Co., Ltd. 337 
 338 
Transparency declaration 339 
DML: Advisory Boards or ad hoc consultancy – Accelerate, Achaogen, Adenium, Alere, 340 
Allecra, Altermune, Astellas, AstraZeneca, Auspherix, Basilea, Bayer, BioVersys, Cubist, 341 
Curetis, Cycle, Discuva, Forest, GSK, Meiji, Pfizer, Roche, Shionogi, Tetraphase, 342 
VenatoRx, Wockhardt; Paid lectures – AOP Orphan, Astellas, AstraZeneca, Bruker, 343 
Curetis, Merck, Pfizer, Leo; shareholdings in– Dechra, GSK, Merck, Perkin Elmer, 344 
Pfizer amounting to <10% of portfolio value. All other authors: No personal interests to 345 
declare. However, PHE’s AMRHAI Reference Unit has received financial support for 346 
conference attendance, lectures, research projects or contracted evaluations from 347 
numerous sources, including: Achaogen, Allecra Antiinfectives, Amplex, AstraZeneca, 348 
Becton Dickinson, British Society for Antimicrobial Chemotherapy, Cepheid, Check-Points, 349 
Cubist, UK Department of Health, UK Food Standards Agency, Glaxo SmithKline, Henry 350 
Stewart Talks, IHMA, Melinta, Merck Sharpe & Dohme, Meiji, Momentum Biosciences, 351 
Nordic, Norgine, Rempex, Rokitan, Smith & Nephew, Trius , VenatoRx, Wockhardt. 352 
 353 
References 354 
1. Livermore DM, Mushtaq S, Warner M et al. Activities of NXL104 combinations 355 
with ceftazidime and aztreonam against carbapenemase-producing 356 
Enterobacteriaceae. Antimicrob Agents Chemother 2011;55:390-4. 357 
2. Aktaş Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in 358 
combination with β-lactams against Gram-negative bacteria, including OXA-48 β-359 
lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2012;39:86-360 
9.  361 
3. Morinaka A Tsutsumi Y, Yamada M et al. OP0595, a new diazabicyclooctane: 362 
mode of action as a serine β -lactamase inhibitor, antibiotic and β -lactam 363 
‘enhancer’. J Antimicrob Chemother, in press 364 
4. Fass RJ. Activity of mecillinam alone and in combination with other -lactam 365 
antibiotics. Antimicrob Agents Chemother 1980;18:906-12. 366 
5. Neu HC. Synergy of mecillinam, a -amidinopenicillanic acid derivative, combined 367 
with -lactam antibiotics.  Antimicrob Agents Chemother 1976;10:535-4. 368 
6. Otsuki M. Synergistic effect of cephalexin with mecillinam. J Antibiot (Tokyo) 369 
1981;34:739-52. 370 
7. Spratt BG.  The mechanism of mecillinam. J Antimicrob Chemother 1977;3 Suppl 371 
B:13-9. 372 
8. Doumith M, Ellington MJ, Livermore DM, Woodford N. Molecular mechanisms 373 
disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter 374 
spp. clinical isolates from the UK. J Antimicrob Chemother 2009;63:659-67. 375 
9. Clinical Laboratory Standards Institute. Methods for Dilution Antimicrobial 376 
Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard M7-377 
A9. Wayne, PA, USA: CLSI; 2011. 378 
10. Chen HY, Livermore DM. Comparative in-vitro activity of biapenem against 379 
enterobacteria with -lactamase-mediated antibiotic resistance. J Antimicrob 380 
Chemother 1994;33:453-64. 381 
11. Oueslati S, Nordmann P, Poirel L. Heterogeneous hydrolytic features for OXA-48-382 
like β-lactamases. J Antimicrob Chemother 2015;70:1059-63  383 
12. Chen HY, Livermore DM. In-vitro activity of biapenem, compared with imipenem 384 
and meropenem, against Pseudomonas aeruginosa strains and mutants with 385 
known resistance mechanisms. J Antimicrob Chemother 1994;33:949-58. 386 
13. Livermore DM, Warner M, Mushtaq S.  Activity of MK-7655 combined with 387 
imipenem against Enterobacteriaceae and Pseudomonas aeruginosa.  J 388 
Antimicrob Chemother 2013;68:2286-90.  389 
14. Zhou XY, Kitzis MD, Gutmann L.  Role of cephalosporinase in carbapenem 390 
resistance of clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents 391 
Chemother 1993;37:1387-9. 392 
15. Livermore DM, Chen HY.  Potentiation of -lactams against Pseudomonas 393 
aeruginosa by Ro 48-1256, a bridged monobactam inhibitor of AmpC -394 
lactamases.  J Antimicrob Chemother 1997;40:335-43. 395 
16. Neu HC. Mecillinam, a novel penicillanic acid derivative with unusual 396 
activity against Gram-negative bacteria. Antimicrob Agents Chemother 1976; 397 
9: 793–9. 398 
17. Legaree BA, Daniels K, Weadge JT et al. Function of penicillin-binding protein 2 in 399 
viability and morphology of Pseudomonas aeruginosa. J Antimicrob Chemother. 400 
2007;59:411-24.  401 
18. Yang Y, Bhachech N, Bush K.  Biochemical comparison of imipenem, meropenem 402 
and biapenem: permeability, binding to penicillin-binding proteins, and stability 403 
to hydrolysis by -lactamases.  J Antimicrob Chemother 1995;35:75-84. 404 
19. Ehmann DE, Jahic H, Ross PL et al. Kinetics of avibactam inhibition against Class 405 
A, C, and D β-lactamases.  J Biol  Chem 2013;288:27960-71. 406 
20. Varma A, Young KD. In Escherichia coli, MreB and FtsZ direct the synthesis of 407 
lateral cell wall via independent pathways that require PBP 2. J Bacteriol 408 
2009;191:3526-33. 409 
21. Vinella D, Cashel M, D'Ari R. Selected amplification of the cell division genes ftsQ-410 
ftsA-ftsZ in Escherichia coli.Genetics 2000;156:1483-92. 411 
22. Young KD. Why spherical Escherichia coli dies: the inside story. J 412 
Bacteriol 2008; 190:1497-8. 413 
23. Thulin E, Sundqvist M, Andersson DI Amdinocillin (mecillinam) resistance 414 
mutations in clinical isolates and laboratory-selected mutants of Escherichia coli.  415 
Antimicrob Agents Chemother 2015;59:1718-27. 416 
24. Wang X, Zhang F, Zhao C et al. In vitro activities of ceftazidime-avibactam and 417 
aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 418 
2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother 419 
2014;58:1774-8. 420 
25. Livermore DM, Warner M, Jamrozy D et al. In-vitro selection of ceftazidime-421 
avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. 422 
Antimicrob Agents Chemother 2015, in press. 423 
 424 
 425 
Table 1.  MIC distribution of OP0595 by species 426 
 427 
 MIC (mg/L) 
 <1 2 4 >4 
E. coli 10 32 4 3 
Enterobacter spp. 9 29 3 9 
Citrobacter spp.  9 1  
Klebsiella spp.  48 44 26 
M. morganii    15 
Serratia spp.   3 12 
P. aeruginosa    40 
A. baumannii   1 29 
 428 
 429 
430 
Table 2.  Activity of lactam OP0595 combinations, and ceftazidime/avibactam versus Enterobacteriaceae groups 431 
 432 
 Count of isolates 
 Aztreonam+OP0595 at (mg/L) Biapenem+OP0595 at (mg/L) Cefepime+OP0595 at (mg/L) Piperacillin+OP0595 at (mg/L) 
Ceftazidime+ 
avibactam at 
(mg/L) 
 0 1 2 4 0 1 2 4 0 1 2 4 0 1 2 4 0 4 
ESBL-producing Enterobacteriaceae, ertapenem susceptible (n=60)a 
R at target MICb  54 3 0 0 0 0 0 0 25 0 0 0 60 4 0 0 57 0 
I at target MICb 6 16 0 0 0 0 0 0 24 0 0 0 0 3 0 0 1 1 
S at target MICb 0 41 60 60 60 60 60 60 11 60 60 60 0 53 60 60 2 59 
Inhibited by 
OP0595 alone, 
cumulative - 6 49 57 - 6 49 57 - 6 49 57 - 6 49 57 -  1c 
                   
AmpC-producing Enterobacteriaceae, ertapenem susceptible (n=60)d 
R at target MICb  32 0 0 0 0 0 0 0 1 0 0 0 56 0 0 0 47 0 
I at target MICb 15 4 0 0 7 6 5 5 4 0 0 0 2 1 0 0 7
e 0 
S at target MICb 13 56 60 60 53 54 55 55 55 60 60 60 2 59 60 60 6
e 60 
Inhibited by 
OP0595 alone, 
cumulative - 4 28 37 - 4 28 37 - 4 28 37 - 4 28 37 - 0 c 
                   
ESBL and AmpC-producing Enterobacteriaceae, ertapenem-resistant via porin loss (n=28)f 
                   
R at target MICb  28 15 3 1 4 0 0 0 22 8 0 0 28 13 5 2 28 1 
I at target MICb 0 5 5 1 14 11 6 1 6 4 4 1 0 6 1 1 0 8 
S at target MICb 0 8 20 26 10 17 22 27 0 16 24 27 0 9 22 25 0 19 
Inhibited by 
OP0595 alone, 
cumulative - 1 8 13 - 1 8 13 - 1 8 13 - 1 8 13 - 0 c 
                   
Enterobacteriaceae isolates with KPC carbapenemases (30)g 
R at target MICb  30 4 1 0 28 1 0 0 29 0 0 0 30 12 0 0 29 2 
I at target MICb 0 2 1 0 2 0 0 0 1 1 0 0 0 5 0 0 1 1 
S at target MICb 0 24 28 30 0 29 30 30 0 29 30 30 0 13 30 30 0 27 
Inhibited by 
OP0595 alone, 
cumulative - 2 17 23 - 2 17 23 - 2 17 23 - 2 17 23 - 0 c 
                   
K. oxytoca hyperproducing K1 lactamase (n=10) 
R at target MICb  10 0 0 0 0 0 0 0 0 0 0 0 10 1 0 0 0 0 
I at target MICb 0 0 0 0 0 0 0 0 0 0 0 0 0 4 1 0 8 0 
S at target MICb 0 10 10 10 10 10 10 10 10 10 10 10 0 5 9 10 2 10 
Inhibited by 
OP0595 alone, 
cumulative - 0 4 9 - 0 4 9 - 0 4 9 - 0 4 9 - 0 c 
                   
Enterobacteriaceae isolates with MBLs (n=40)h 
R at target MICb  26 1 0 0 20 10 4 3 39 20 8 3 40 15 4 1 40 39 
I at target MICb 1 3 1 0 10 5 3 1 1 5 1 2 0 5 1 0 0 1 
S at target MICb 13 36 39 40 10 25 33 36 0 15 31 35 0 20 35 39 0 0 
Inhibited by 
OP0595 alone, 
cumulative - 5 19 31 - 5 19 31 - 5 19 31 - 5 19 31 - 0 c 
                   
Enterobacteriaceae (all K. pneumoniae) isolates with OXA-48 carbapenemases (n=10)i 
R at target MICb  8 1 0 0 5 4 1 1 8 1 0 0 10 4 0 0 8 0 
I at target MICb 0 0 0 0 3 2 3 1 2 1 0 0 0 1 0 0 0 0 
S at target MICb 2 9 10 10 2 4 6 8 0 8 10 10 0 5 10 10 2 10 
Inhibited by 
OP0595 alone, 
cumulative - 0 3 6 - 0 3 6 - 0 3 6 - 0 3 6 - 0 c 
                   
ESBL, AmpC, carbapenemase negative Enterobacteriaceae control isolates (n=40)j 
R at target MICb  0 0 0 0 0 0 0 0 0 0 0 0 9 0 0 0 0 0 
I at target MICb 0 0 0 0 3 2 2 2 0 0 0 0 9 0 0 0 0 0 
S at target MICb 40 40 40 40 37 38 38 38 40 40 40 40 22 40 40 40 40 40 
Inhibited by 
OP0595 alone, 
cumulative - 8 24 30 - 8 24 30 - 8 24 30 - 8 24 30 - 0 c 
 433 
 434 
a 20 E. coli, 20 Enterobacter spp., 20 K. pneumoniae 435 
b Aztreonam, biapenem, cefepime and ceftazidime all categorised as S <1 mg/L, I 2-4 mg/L, R >4 mg/L; piperacillin as S <8, I = 16 mg/L and R >16 mg/L; these 436 
values were adopted as the more stringent of EUCAST or CLSI breakpoints for the partner-lactams and therefore the lowest likely to be adopted for any 437 
future combination.  As such they should be seen as a ‘worst case scenario’ and the US Food and Drug Administration has recently granted a higher (8+4 438 
mg/L susceptibility) breakpoint to ceftazidime/avibactam.   Numbers in the susceptible category are shown in bold font wherever 90% or more of the isolates 439 
are inhibited. 440 
c Inhibited by 4 mg/L avibactam alone 441 
d 10 E. coli and 10 Klebsiella spp. with plasmid AmpC; 10 Enterobacter spp. 10 Citrobacter spp., 10 M. morganii and 10 Serratia spp. with derepressed 442 
chromosomal AmpC.  Among 23 isolates with OP0595 MICs >4 mg/L, 20 were Morganella and Serratia. All the biapenem ‘intermediate’ isolates were M. 443 
morganii. 444 
e 10/13 Ceftazidime-susceptible or intermediate isolates were Serratia spp. 445 
f 9 E. coli and 9 Klebsiella spp. with ESBLs and porin loss; 10 Enterobacter spp. with derepressed AmpC + porin loss  446 
g 5 E. coli, 20 Klebsiella spp. and 5 Enterobacter spp. 447 
h 10 E. coli, 20 Klebsiella spp 10 Enterobacter; 13 with IMP, 9 with VIM, 18 and with NDM carbapenemases. 448 
i 10 Klebsiella spp. 449 
j 10 E. coli, 10 Klebsiella spp., 10 Enterobacter spp. 5 M. morganii and 5 Serratia spp.  All the 10 with OP0595 MICs >4 mg/L were M. morganii and Serratia 450 
spp.; 451 
all biapenem ‘intermediate’ isolates were M. morganii 452 
- No diazabicyclooctane present, therefore no activity attributable to it. 453 
 454 
 455 
456 
Table 3.   Response of carbapenemase-negative Enterobacteriaceae isolates with OP0595 MICs >4 mg/L to OP0595 combinations  457 
 458 
 MICs (mg/L) 
 Aztreonam+OP0595 at (mg/L) Biapenem+OP0595 at (mg/L) Cefepime+OP0595 at (mg/L) Piperacillin+OP0595 at (mg/L) Ceftazidime+ 
avibactam 
(mg/L) 
 0 1 2 4 0 1 2 4 0 1 2 4 0 1 2 4 0 4 
ESBL producing Enterobacteriaceae; ertapenem susceptible (n=3) 
Range 256 2-4 0.12-
1 
<0.02
-0.06 
0.25-
1 
0.06-
0.5 
<0.02
-0.5 
0.03-
0.5 
4 0.03-
0.12 
<0.02
-0.06 
<0.02 >256 8 0.5-4 <0.12
-0.25 
64-
256 
0.25-
0.5 
Geom. mean 256 2.5 0.32 0.037 0.40 0.20 0.12 0.12 4 0.078 0.023 0.014 >256 8.0 1.0 0.16 101.5 0.40 
                   
ESBL-producing Enterobacteriaceae; ertapenem resistant (n=9) 
Range 64-
>256 
1-128 0.03-
8 
<0.02
-4 
1-8 0.5-4 0.25-
2 
0.03-
2 
16-
>256 
1-64 0.03-
4 
<0.02
-1 
>256 8-
>256 
0.25-
>256 
<0.12
-32 
16-
>256 
0.5-2 
Geom. mean 219.5 12.7 0.62 0.075 2.5 1.3 0.79 0.39 188.2 8.6 0.36 0.069 >256 109.7 8.0 1.0 138.3 1.2 
                   
AmpC-hyperproducing producing Enterobacteriaceae, E. coli, Enterobacter spp., Klebsiella spp.; ertapenem susceptible (n = 6) 
Range 0.5-
64 
0.03-
2 
<0.02
-0.25 
<0.02
-0.25 
0.12-
1 
0.03-
1 
<0.02
-0.5 
<0.02
-0.5 
0.12-
1 
<0.02
-0.06 
<0.02
-0.06 
<0.02
-0.06 
32-
>256 
2-8 <0.12
-2 
<0.12
-2 
16-
256 
0.25-
0.5 
Geom. Mean MIC 
(mg/L) 
12.7 0.31 0.026 0.023 0.40 0.097 0.060 0.047 0.28 0.042 0.018 0.018 114.0 2.8 0.25 0.25 50.8 0.40 
                   
AmpC-hyperproducing M. morganii (n=10) 
Range 0.03-
32 
0.03-
2 
<0.02
-1 
<0.02
-1 
1-4 0.5-2 1-2 0.5-2 0.03-
1 
<0.02
-0.25 
<0.02
-0.25 
<0.02
-0.25 
8-
>256 
0.25-
16 
0.25-
4 
<0.12
-2 
2-
>256 
0.03-
1 
Geom. mean 1.1 0.14 0.099 0.059 1.7 1.4 1.4 1.2 0.12 0.048 0.042 0.036 111.4 1.4 0.81 0.38 24.3 0.18 
                   
AmpC-hyperproducing S. marcescens (n=7) 
Range 0.12-
8 
0.12 
-1 
0.03-
0.5 
<0.02
-0.12 
012 
-1 
0.12 
-1 
0.12 
-1 
<0.02
-1 
0.06-
2 
0.06 
-0.5 
<0.02
-0.5 
<0.02
-0.12 
4-128 1-8 <0.12
2 
<0.12
-0.5 
0.12-
2 
0.06-
1 
Geom. mean 1.6 0.37 0.14 0.029 0.41 0.31 0.28 0.12 0.41 0.17 0.073 0.024 29.0 3.6 0.91 0.20 0.67 0.23 
                   
E. coli, Enterobacter spp., Klebsiella spp. with AmpC and porin loss, ertapenem resistant (n=6) 
Range 64-
>256 
4- 
256 
0.12-
128 
0.03-
16 
1-8 1-4 0.5-4 0.06-
1 
4-16 0.25-
8 
0.06-
4 
0.03-
2 
128-
>256 
4-
>256 
1-256 <0.12
-32 
128-
>256 
1-32 
Geom. mean 128.0 16.0 2.5 0.31 2.8 2.2 1.4 0.44 6.4 0.89 0.35 0.076 203.2 14.3 5.0 0.63 203.2 2.5 
 459 
 460 
461 
Table 4.  MICs (mg/L) of OP0595 combinations versus carbapenemase-producing Enterobacteriaceae isolates with OP0595 MICs >4 mg/L. 462 
 463 
   Aztreonam+OP0595 at (mg/L) Biapenem+OP0595 at (mg/L) Cefepime+OP0595 at (mg/L) Piperacillin+OP0595 at (mg/L) 
Ceftazidime+ 
avibactam 
(mg/L) 
   0 1 2 4 0 1 2 4 0 1 2 4 0 1 2 4 0 4 
H587 E. cloacae KPC >256 4 0.03 <0.02 8 0.5 0.03 <0.02 32 0.5 <0.02 <0.02 >256 128 <0.12 <0.12 128 1 
H401 E. cloacae KPC >256 32 8 0.06 4 0.5 0.5 0.25 32 1 0.25 <0.02 256 16 4 <0.12 >256 8 
H451 K. pneumoniae KPC >256 1 0.12 <0.02 >256 8 1 0.06 >256 0.25 <0.02 <0.02 >256 32 0.5 <0.12 >256 1 
H316 K. pneumoniae KPC >256 1 <0.02 <0.02 32 0.25 <0.02 <0.02 32 0.12 <0.02 <0.02 >256 32 <0.12 <0.12 32 0.5 
H467 K. pneumoniae KPC >256 16 0.06 <0.02 32 1 0.12 0.03 256 1 <0.02 <0.02 >256 32 <0.12 <0.12 256 0.5 
H538 K. pneumoniae KPC 256 2 0.12 0.06 32 1 0.5 0.5 8 0.25 <0.02 <0.02 >256 32 1 0.5 32 0.5 
H458 K. pneumoniae KPC >256 1 0.03 <0.02 32 0.5 0.03 <0.02 128 0.25 <0.02 <0.02 >256 64 0.25 <0.12 64 1 
H483 K. pneumoniae OXA-48 0.25 0.06 0.03 <0.02 32 16 16 8 2 0.25 0.03 0.03 >256 32 2 2 0.5 0.25 
H386 K. pneumoniae OXA-48 >256 1 0.12 0.06 8 8 4 4 >256 2 0.12 0.06 >256 32 8 4 256 1 
H329 K. pneumoniae OXA-48 128 0.5 <0.02 <0.02 4 2 1 0.06 >256 0.5 0.12 0.03 >256 64 0.5 <0.12 64 0.5 
H706 K. pneumoniae OXA-48 128 0.25 0.03 0.03 4 2 2 1 >256 0.5 0.03 0.03 >256 16 2 0.5 64 0.25 
H373 E. cloacae IMP 0.5 0.5 0.12 <0.02 16 32 16 8 128 256 256 16 64 128 32 2 >256 >256 
H555 K. pneumoniae IMP 0.25 0.12 0.03 0.03 2 2 1 1 16 4 4 2 64 16 0.5 0.5 >256 >256 
H370 K. pneumoniae IMP 64 0.25 <0.02 <0.02 8 16 2 2 128 128 16 2 >256 32 2 0.25 >256 >256 
H538 Klebsiella spp. IMP 0.5 0.25 0.25 <0.02 128 128 128 128 128 16 64 8 64 16 8 0.5 >256 >256 
H459 K. pneumoniae VIM 2 0.03 <0.02 <0.02 1 0.5 0.5 0.06 4 0.12 0.03 <0.02 >256 8 <0.12 <0.12 128 2 
H744 K. pneumoniae VIM 0.25 0.03 <0.02 <0.02 32 4 4 0.5 64 2 0.5 0.03 >256 0.5 <0.12 <0.12 >256 >256 
H254 K. pneumoniae NDM 128 0.5 <0.02 <0.02 4 4 0.03 0.03 64 128 0.03 0.03 >256 >256 <0.12 <0.12 >256 >256 
H282 K. pneumoniae NDM 128 1 0.03 <0.02 128 64 1 <0.02 >256 256 32 <0.02 >256 >256 16 <0.12 >256 >256 
H519 K. pneumoniae NDM >256 0.25 0.06 0.06 16 16 16 16 256 64 16 16 >256 >256 32 32 >256 >256 
 464 
 465 
466 
Table 5.  Interactions between OP0595 and partner antibiotics for groups of non-fermenters 467 
 468 
  Geometric mean MIC (mg/L) 
Group n Aztreonam Biapenem Cefepime Piperacillin Ceftazidime 
  Alone +OP0595 
4 mg/L 
Alone +OP0595 
4 mg/L 
Alone +OP0595 
4 mg/L 
Alone +OP0595 
4 mg/L 
Alone +avibactam 
4 mg/L  
P. aeruginosa            
Controls, fully susceptible 10 2.3 2.0 0.38 0.16 2.6 2.5 6.9 3.0 1.6 1.3 
Derepressed AmpC, Imipenem S 9 27.4 4.0 0.73 0.17 17.3 5.0 161.3 8.0 40.3 2.3 
Derepressed AmpC, Imipenem NS 11 68.2 4.8 9.7 1.8 34.1 4.3 240.4 12.4 82.3 3.8 
PER or VEB ESBLs 5 222.9 10.6 0.57 0.22 84.5 3.0 36.8 4.6 >256 7.0 
IMP or VIM MBLs 5 13.9 10.6 97.1 97.1 64.0 64.0 168.9 97.0 111.5 73.5 
A. baumannii            
Controls, full susceptible 10 13.9 12.1 0.14 0.14 3.0 3.7 14.9 4.6 3.5 3.2 
AmpC-mediated cephalosporin resistance 10 34.3 17.0 0.31 0.16 14.9 7.9 222.9 13.0 39.4 10.6 
OXA carbapenemases 5 55.7 64 12.1 10.6 27.8 32 >256 194.0 111.4 32.0 
IMP or NDM MBLs 5 36.8 48.5 16.0 7.0 128.0 111.5 168.9 128.0 194.1 168.9 
 469 
 470 
